Publications

The Annals of otology, rhinology, and laryngology

A Prospective Multicenter Observational Study Investigating the Concordance Between Patient-Reported Hearing Loss and Commonly Used Ototoxicity Grading Systems in Patients Treated with Platinum-Based Chemotherapy.

01-06-2026

Nature medicine

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

01-03-2026

European journal of nuclear medicine and molecular imaging

[¹⁸F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

01-03-2026

BMJ open

Transtympanic sodium thiosulphate to prevent cisplatin-related hearing loss: a protocol for randomised controlled multicentre phase III trial, the SOUND trial.

03-12-2025

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Key Publication

Frontiers in oncology

Surgeon's perceptions on 3D visualization methods in parotid gland tumor surgery.

08-10-2025

Oral oncology

Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.

01-05-2025

Head & neck

The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.

01-01-2025

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer.

01-12-2024

JCI insight

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

08-11-2024

The New England journal of medicine

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

07-11-2024

Cancer medicine

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

01-08-2024

Molecular cancer

Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients.

04-06-2024

Cell

A pan-cancer analysis of the microbiome in metastatic cancer.

25-04-2024

Cellular & molecular immunology

CD4⁺ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.

01-04-2024

Nature communications

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

21-03-2024

Facial plastic surgery : FPS

Optimizing Wound Care after Surgery of the Head and Neck: A Review of Dressing Materials.

01-02-2024

Nature medicine

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.

01-12-2023

Cancer discovery

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

05-10-2023

The Journal of clinical investigation

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.

02-10-2023

Annals of surgical oncology

Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma.

01-08-2023

European journal of cancer (Oxford, England : 1990)

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.

01-05-2023

Journal of surgical oncology

Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.

01-04-2023

Cancers

Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019).

28-02-2023

Melanoma research

Talimogene laherparepvec monotherapy for head and neck melanoma patients.

01-02-2023

Cancers

Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma.

17-12-2022

Cancers

Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma.

23-11-2022

International journal of oral and maxillofacial surgery

Registration methods for surgical navigation of the mandible: a systematic review.

01-10-2022

Immuno-oncology technology

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

01-09-2022

Annals of surgical oncology

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

01-08-2022

Critical reviews in oncology/hematology

Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis.

01-07-2022

International journal of computer assisted radiology and surgery

A hybrid registration method using the mandibular bone surface for electromagnetic navigation in mandibular surgery.

01-07-2022

Annals of surgical oncology

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

01-06-2022

Nature medicine

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

01-06-2022

European journal of nuclear medicine and molecular imaging

[¹⁸F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.

01-05-2022

JAMA surgery

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.

01-04-2022

Nature communications

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

22-12-2021

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes.

01-09-2021

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Therapeutic neck dissection in head and neck melanoma patients: Comparing extent of surgery and clinical outcome in two cohorts.

01-09-2021

Cancer immunology, immunotherapy : CII

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.

01-08-2021

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.

01-06-2021

Annals of oncology : official journal of the European Society for Medical Oncology

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

01-06-2021

Cancer immunology, immunotherapy : CII

Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.

01-05-2021

Nature medicine

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

01-02-2021

Proceedings of the National Academy of Sciences of the United States of America

Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.

30-06-2020

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation.

01-01-2020

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.

01-01-2020

Blood advances

Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair.

26-11-2019

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology

Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology.

01-08-2019

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery

Organ Function Preservation Failure after (Chemo)Radiotherapy in Head and Neck Cancer: A Retrospective Cohort Analysis.

01-08-2019

A Prospective Multicenter Observational Study Investigating the Concordance Between Patient-Reported Hearing Loss and Commonly Used Ototoxicity Grading Systems in Patients Treated with Platinum-Based Chemotherapy.

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

[18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

Transtympanic sodium thiosulphate to prevent cisplatin-related hearing loss: a protocol for randomised controlled multicentre phase III trial, the SOUND trial.

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Surgeon's perceptions on 3D visualization methods in parotid gland tumor surgery.

Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.

The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer.

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients.

A pan-cancer analysis of the microbiome in metastatic cancer.

CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

Optimizing Wound Care after Surgery of the Head and Neck: A Review of Dressing Materials.

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial.

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.

Oncological Outcome After Lymph Node Dissection for Cutaneous Squamous Cell Carcinoma.

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.

Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.

Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019).

Talimogene laherparepvec monotherapy for head and neck melanoma patients.

Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma.

Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma.

Registration methods for surgical navigation of the mandible: a systematic review.

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis.

A hybrid registration method using the mandibular bone surface for electromagnetic navigation in mandibular surgery.

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.

[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

Reduction of GTV to high-risk CTV radiation margin in head and neck squamous cell carcinoma significantly reduced acute and late radiation-related toxicity with comparable outcomes.

Therapeutic neck dissection in head and neck melanoma patients: Comparing extent of surgery and clinical outcome in two cohorts.

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.

Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.

Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.

Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.

Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation.

Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.

Activated neutrophils exert myeloid-derived suppressor cell activity damaging T cells beyond repair.

Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its Pathophysiology.

Organ Function Preservation Failure after (Chemo)Radiotherapy in Head and Neck Cancer: A Retrospective Cohort Analysis.

This site uses cookies

[¹⁸F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

CD4⁺ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors.

[¹⁸F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.